A real world study of the first bevacizumab biological analogue in China (Ankeda) in patients with locally advanced or metastatic non squamous NSCLC

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039826

Enrollment

Unknown

Registered

2020-11-11

Start date

2020-11-20

Completion date

Unknown

Last updated

2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Case series:metaphase

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Local advanced or metastatic non squamous NSCLC was diagnosed by histopathology; 2. ECOG score was 0-2; 3. The patients need to be treated with Ankeda (single drug or combination therapy).

Exclusion criteria

Exclusion criteria: 1. Recent active bleeding or hemoptysis (>=1/2 teaspoon blood); 2. Uncontrolled hypertension and hypertensive crisis patients; 3. Major traumatic surgery is planned within 4 weeks before administration or during the study period, or the wound is not fully healed within 4 weeks before administration; 4. Patients with previous digestive tract perforation or fistula, or patients with perforation or fistula after using bevacizumab before; 5. Pregnant or lactating women, and men and women who refuse to take effective contraceptive measures.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate;	—

Countries

China

Contacts

Public ContactHaiping Zheng

Department of Oncology, the First Affiliated Hospital of Guangxi Medical University

zhenghaiping@163.com+86 13878862418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026